万邦德：石杉碱甲控释片Ⅱ/Ⅲ期临床试验完成50例受试者入组

Group 1 - The core announcement is that Wanbangde (002082) has completed the enrollment of 50 subjects for its Phase II/III pivotal registration clinical trial of the new drug, Huperzine A controlled-release tablets, aimed at treating mild to moderate Alzheimer's disease [1] Group 2 - The drug is classified as a Class 2 new drug, indicating its potential significance in the pharmaceutical market [1] - The completion of subject enrollment marks a critical step in the clinical trial process, which is essential for regulatory approval [1] - The trial's focus on Alzheimer's disease highlights the growing demand for effective treatments in this therapeutic area, reflecting broader industry trends [1]